jnj-39758979
Small moleculeexperimental
Clinical trial activity
7 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2009 (NCT00946569)
Timeline
Indications
Mechanism of action
- Histamine H4 receptorINHIBITOR
HRH4 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)c1cc(N2CC[C@@H](N)C2)nc(N)n1- Mol. weight
- 221.31 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3236549 ↗
Also known as
- jnj39758979
- jnj39758979
- jnj-39758979
- jnj-39758979
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01493882 | Phase 2 | Mar 1, 2012 | Johnson and Johnson |
| NCT01480388 | Phase 2 | Dec 1, 2011 | Johnson and Johnson |
| NCT01497119 | Phase 2 | Oct 1, 2011 | Janssen Pharmaceutica NV, Johnson and Johnson |
| NCT01442545 | Phase 1 | Aug 1, 2011 | Johnson and Johnson |
| NCT01081821 | Phase 1 | Feb 1, 2010 | Johnson and Johnson |
| NCT01068223 | Phase 1 | Feb 1, 2010 | Johnson and Johnson |
| NCT00946569 | Phase 2 | Aug 1, 2009 | Johnson and Johnson |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Johnson and Johnson | For profit | 7 | 7 | 2 | 2009 |
| Janssen Pharmaceutica NV | For profit | 1 | 0 | 1 | 2011 |
2 organizations
Page 1 / 1